Enzyme Education Probiotics Full Systemic Enzymes Hybrid Systemic Enzymes Digestive Enzymes Enzymes
Knowledge Base:  
Serrapeptase: Acute or Chronic Inflammation of Otorhinolaryngology Pathology
Last Updated: 02/18/2011

Evaluation of Serratia Peptidase in Acute or Chronic Inflammation of Otorhinolaryngology Pathology: a Multicentre, Double-blind, Randomized Trial versus Placebo

 

A. Mazzone, M. Catalan, M. Costanzo, A. Drusian, A. Mandol, S. Russo, E. Guarini and G. Vesperini 

 

The efficacy and tolerability of Serratia peptidase were evaluated in a multi-centre, double-blind, placebo-controlled study of 193 subjects suffering from acute or chronic ear, nose or throat disorders. Treatment lasted 7 - 8 days, with the drug or placebo being administered at a rate of two tablets three times a day. After 3-4 days' treatment, significant symptom regression was observed in peptidase-treated patients. There was also a significant reduction in symptoms after 7 -8 days for patients in both treatment groups but the response was more marked in those patients receiving the active drug. Statistical comparison between the two groups confirmed the greater efficacy and rapid action of the peptidase against all the symptoms examined at both stages. Tolerance was found to be very good and similar for both groups. It is concluded that Serratia peptidase has anti-inflapimatory, anti-edemic and fibrinolytic activity and acts rapidly on localized inflammation. 



Was this article helpful?

Comments:
 

Related Articles
 > A preliminary trial of serrapeptase in patients with carpal tunnel syndrome.
 > A New Treatment for Prosthetic Infections?
 > Serrapeptase: Treatment of Breast Engorgement
 > Serrapeptase: Post-antrotomy Buccal Swelling
Newsletter Sign Up
Sign up for special offers and promotions.
Company
Customer Service
Get the Latest News
Read up on our blog and recent postings.
Copyright © Express Naturals. 2011. All Rights Reserved. Design by Built-

Built with Volusion